Morningstar, Inc.
MORN
$166.22
-5.46%
Morningstar, Inc. is a leading provider of independent investment research, data, and analytics to financial advisers, asset managers, and investors, operating in the Financial - Data & Stock Exchanges industry. The company is distinguished as a trusted, independent platform for investment insights, with a diversified portfolio spanning its flagship Morningstar Direct Platform, PitchBook, and wealth and retirement solutions. The current investor narrative is dominated by a significant stock price correction and concerns over growth deceleration, as evidenced by the sharp decline from its 52-week high, with attention focused on the company's ability to stabilize its core subscription-based revenue streams and navigate a challenging market environment for financial data providers.…
MORN
Morningstar, Inc.
$166.22
Investment Opinion: Should I buy MORN Today?
Rating: Hold. The core thesis is that Morningstar is a fundamentally strong company caught in a growth transition, with its deeply discounted forward P/E of 13.0x offering a margin of safety, but lacking a near-term catalyst for a re-rating amidst persistent technical weakness.
Supporting evidence includes the attractive forward P/E of 13.0x versus a trailing P/E of 24.3x, the robust profitability metrics (61.1% gross margin, 30.6% ROE), and the substantial TTM free cash flow of $442.6 million. However, these strengths are counterbalanced by decelerating Q4 revenue growth of 8.5% and a contracting net margin, which validate the market's caution.
The thesis would upgrade to a Buy if revenue growth re-accelerates above 10% or if the forward P/E compresses further toward 10x, offering a greater valuation cushion. It would downgrade to a Sell if revenue growth falls below 5% or if the stock decisively breaks below the $149 support level. Currently, the stock appears fairly valued relative to its near-term growth prospects but undervalued relative to its long-term cash-generative business model.
Sign up to view all
MORN 12-Month Price Forecast
Morningstar presents a classic 'value trap' versus 'deep value' dilemma. The business quality is high, evidenced by stellar returns on equity and strong cash flows, and the valuation is at a multi-year low. However, the deteriorating growth trajectory is a legitimate concern that currently outweighs the valuation appeal. The stance is neutral, as the stock likely oscillates in a range until growth stabilizes. An upgrade to bullish would require consecutive quarters of revenue growth stabilization or acceleration above 10%. A downgrade to bearish would be triggered by a breakdown below the $149 support, signaling the value thesis has broken.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Morningstar, Inc.'s 12-month outlook, with a consensus price target around $216.09 and implied upside of +30.0% versus the current price.
Average Target
$216.09
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$133 - $216
Analyst target range
Analyst coverage for Morningstar is extremely limited, with only 2 analysts providing estimates, indicating insufficient coverage for a robust consensus view. This sparse coverage typically reflects a mid-cap stock with lower institutional visibility, which can contribute to higher volatility and less efficient price discovery as the market lacks a broad range of professional opinions to anchor valuation. Without a published consensus price target or recommendation distribution, the investment thesis relies more heavily on independent fundamental and technical analysis rather than crowd-sourced analyst sentiment.
Bulls vs Bears: MORN Investment Factors
The evidence currently tilts bearish, as the primary driver of the investment thesis—growth deceleration—remains unresolved and is actively pressuring both the stock price and profit margins. However, the bearish case is now heavily reflected in the valuation, with the forward P/E of 13.0x pricing in significant pessimism. The single most important tension is whether the 8.5% revenue growth represents a sustainable new normal or a cyclical trough. If growth stabilizes or re-accelerates, the deeply discounted valuation and strong cash flows could catalyze a sharp rebound. Conversely, if growth decelerates further, the stock's technical support at $149 could be tested, extending the downtrend.
Bullish
- Deeply Undervalued Forward P/E: The stock trades at a forward P/E of 13.0x, a significant discount to its trailing P/E of 24.3x, implying the market expects a strong earnings rebound. This valuation is also near the low end of its multi-year historical range, which has frequently exceeded 40x, suggesting a potential value opportunity if fundamentals stabilize.
- Strong Profitability and Cash Generation: Morningstar maintains robust profitability with a Q4 gross margin of 61.1% and a trailing twelve-month free cash flow of $442.6 million. The company's return on equity of 30.6% is exceptionally high, indicating efficient use of shareholder capital.
- Solid Financial Position: The company has a manageable debt-to-equity ratio of 1.15 and a current ratio near 1.0, indicating a balanced capital structure and sufficient liquidity. This financial stability provides a buffer against market headwinds and funds potential growth initiatives.
- Oversold Technical Condition: The stock price at $169.03 is positioned at just 53% of the distance from its 52-week low ($149.08) to its high ($316.71), indicating it is deeply oversold. This extreme technical positioning, following a -40.3% one-year decline, may represent a contrarian entry point if the downtrend reverses.
Bearish
- Severe Growth Deceleration: Q4 2025 revenue growth decelerated to 8.5% YoY, down from stronger prior-year quarters, signaling a potential normalization in demand for its core data and research services. This deceleration is the primary driver of the stock's significant price correction and raises concerns about future top-line momentum.
- Profitability and Margin Compression: The Q4 2025 net margin of 17.95% declined from 19.78% in the year-ago quarter, reflecting pressure on operating leverage. The operating margin also contracted sequentially from Q3 to Q4, indicating rising costs or competitive pressures are impacting earnings quality.
- Persistent and Severe Downtrend: The stock is in a pronounced bear market, down -40.3% over one year and -20.4% over six months, with no technical confirmation of a reversal. With a beta of 1.11, it has underperformed the S&P 500 by nearly 70 percentage points over the past year, showing extreme relative weakness.
- Limited Analyst Coverage and Visibility: Only two analysts provide coverage, indicating low institutional visibility and potentially less efficient price discovery. The lack of a broad consensus target or rating increases reliance on volatile market sentiment rather than fundamental anchors.
MORN Technical Analysis
The stock is in a pronounced and sustained downtrend, with a 1-year price change of -40.31% and a 6-month decline of -20.38%. Currently trading at $169.03, the price sits near the lower end of its 52-week range, positioned at just 53% of the distance from its 52-week low of $149.08 to its high of $316.71, indicating the stock is deeply oversold and may represent a value opportunity, though it remains a 'falling knife' within a strong bearish trend. Recent short-term momentum shows continued weakness, with a 1-month decline of -0.39% and a 3-month drop of -16.36%, which, while less severe than the annual loss, still confirms the prevailing negative trend without any meaningful divergence or sign of reversal. The stock exhibits high volatility, with a beta of 1.11 indicating it is 11% more volatile than the broader market, and key technical support is clearly defined at the 52-week low of $149.08, while resistance is far above at $316.71; a sustained break below the $149 support would signal a new leg down, whereas a recovery above the $190-$200 area would be needed to suggest a potential bottoming process is underway.
Beta
0.98
0.98x market volatility
Max Drawdown
-50.9%
Largest decline past year
52-Week Range
$149-$317
Price range past year
Annual Return
-45.9%
Cumulative gain past year
| Period | MORN Return | S&P 500 |
|---|---|---|
| 1m | -5.8% | +8.2% |
| 3m | +7.9% | +9.0% |
| 6m | -21.6% | +10.5% |
| 1y | -45.9% | +26.5% |
| ytd | -21.0% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MORN Fundamental Analysis
Revenue growth has been positive but is showing signs of deceleration; the most recent Q4 2025 revenue was $641.1 million, representing an 8.5% year-over-year increase, yet this growth rate has moderated from stronger prior-year quarters, indicating a potential normalization in demand for its data and research services. The company remains profitable with a Q4 2025 net income of $115.1 million and a robust gross margin of 61.1%, but profitability metrics have shown some pressure, as the net margin of 17.95% in Q4 2025 is down from 19.78% in the year-ago quarter, reflecting a compression in operating leverage. Morningstar maintains a solid financial position with a trailing twelve-month free cash flow of $442.6 million, a strong return on equity of 30.6%, and a manageable debt-to-equity ratio of 1.15, indicating it generates ample cash to fund operations and growth while carrying a moderate level of financial leverage.
Quarterly Revenue
$641100000.0B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.61%
Latest Quarter
Free Cash Flow
$442600000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MORN Overvalued?
Given a positive net income, the primary valuation metric is the P/E ratio. The trailing P/E stands at 24.3x, while the forward P/E is significantly lower at 13.0x, indicating the market expects a substantial rebound in earnings, likely priced into the depressed stock. Compared to sector averages (data not available in the provided set), a precise peer comparison cannot be quantified, but the forward P/E of 13.0x appears reasonable for a profitable, cash-generative business, suggesting the steep price decline may have washed out excessive valuation premiums. Historically, the stock's own trailing P/E of 24.3x is well below its recent historical range, which has frequently exceeded 40x and even 50x in prior years, placing it near the lower end of its multi-year valuation band and potentially signaling a value opportunity if the company's fundamentals stabilize.
PE
24.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -284x~697x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks center on the deceleration of the core revenue engine and associated margin pressure. Q4 revenue growth slowed to 8.5% YoY, and the net margin compressed by nearly 200 basis points year-over-year. While free cash flow remains strong at $442.6 million TTM, a continuation of this trend could challenge the high-return-on-equity (30.6%) profile and call into question the sustainability of the current valuation multiples, which are predicated on a forward earnings rebound.
Market and competitive risks are heightened by the stock's severe underperformance. Trading at a forward P/E of 13x, the valuation has compressed dramatically from historical levels above 40x, but this may reflect a permanent de-rating rather than a temporary discount. The high beta of 1.11 indicates the stock is sensitive to broader market swings, and its concentration in financial services data makes it vulnerable to sector-specific downturns or budget cuts by asset managers and advisors.
The worst-case scenario involves a failure to stabilize growth, leading to consecutive earnings misses and multiple compression. In this adverse scenario, the stock could retest and break its 52-week low of $149.08, representing a downside of approximately -12% from the current price of $169. A more severe bear case, aligning with the stock's maximum drawdown of -50.9%, suggests a theoretical downside to the $155-$160 range is plausible if negative momentum persists and investor sentiment remains deeply pessimistic.
FAQ
The key risks are, in order of severity: 1) Growth Deceleration Risk: Revenue growth slowed to 8.5% YoY in Q4 2025; a further slowdown would crush the valuation thesis. 2) Technical/Momentum Risk: The stock is in a severe downtrend, down -40.3% over one year, which can become self-fulfilling. 3) Margin Compression Risk: The net margin fell from 19.78% to 17.95% YoY in Q4, threatening profitability. 4) Market Sensitivity Risk: With a beta of 1.11, the stock is prone to underperform in a declining market, as evidenced by its -69.3% relative strength vs. the S&P 500 over one year.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $180 and $220, assuming current ~8.5% revenue growth and compressed margins persist. The Bull Case (25% probability) targets $240-$280, requiring a growth re-acceleration and valuation re-rating. The Bear Case (15% probability) risks a fall to the $149-$165 range if growth deteriorates further. The base case is most likely, implying limited near-term upside until the growth trajectory becomes clearer. The lack of a broad analyst consensus adds uncertainty to this forecast.
MORN appears undervalued based on its historical valuation and business quality, but fairly valued relative to its near-term growth prospects. The forward P/E of 13.0x is near the low end of its multi-year range and discounts a significant earnings rebound. Compared to its own trailing P/E of 24.3x, the stock is cheap. The market is currently valuing MORN as a slow-growth cash cow rather than the premium growth stock it was perceived as in the past. This valuation implies the market expects the recent growth deceleration to persist.
MORN is a speculative buy for value investors with a high risk tolerance and a long time horizon. The forward P/E of 13.0x is compelling for a company with a 30.6% return on equity and strong free cash flow, suggesting significant upside if growth stabilizes. However, the severe -40.3% price decline and decelerating revenue growth to 8.5% present substantial near-term risk. It is not a good buy for short-term traders or investors seeking stable growth, but could be a good buy for contrarians willing to bet on a turnaround in the company's growth narrative.
MORN is suitable only for long-term investment with a minimum holding period of 2-3 years. The stock's high volatility (beta 1.11) and entrenched downtrend make it a poor candidate for short-term trading. A long-term horizon is necessary to allow the company's fundamental strengths—its strong brand, cash flows, and market position—to potentially overcome the current growth challenges and for the valuation discount to be recognized. The minimal dividend yield of 0.84% indicates it is not an income stock, further emphasizing that the investment case is based on capital appreciation over time.